Teva Pharmaceutical has seen a significant surge in its stock recently, fuelled by a series of positive events. The company reported jump in the stock due to promising results corresponding
schizophrenia treatment and an
upgraded price target by Bank of America. Teva also had an unusual call options activity post their Q1 results which further pushed the stock up by 27%, although it still lags behind the industry. The drugmaker's
Adderall is now back in stock, posing a valuable proposition for value investors. Institutional investors, with a 67% ownership, have vital stakes in the company. Teva's balance sheet, however, remains somewhat strained. Managing to beat Q1 revenue expectations, Teva saw a jump in stock despite missing the EPS. The company secured a
$1.5 billion deal for an inflammation drug, pushing the stock higher. After facing a difficult market, Teva is just one of three generic drug stocks to watch. Amid peaks and valleys, Teva Pharmaceutical remains a favorite amongst institutional investors, who own 65%. Rumors of a comeback in 2024 and a bullish outlook for the company's Austedo franchise have posed important signifiers for potential investors.
Teva Pharmaceutical Stocks News Analytics from Wed, 02 Aug 2023 07:00:00 GMT to Thu, 30 May 2024 16:23:19 GMT -
Rating 7
- Innovation 3
- Information 6
- Rumor -2
